The CEO says keep performing and the market will follow. The second-quarter numbers show what performing now costs: more patients, cheaper units, and a reported P&L propped up by an accounting reversal with no cash behind it.
Novo Nordisk beat expectations, raised guidance for the second time this year, and watched its US-listed shares fall about 6% anyway. The reason is not sentiment. The Wegovy pill that is winning back prescriptions sells for as little as $149 a month against $349 for the injection it replaces, so every patient Novo converts is worth less than the patient Novo already had. Volume and revenue have come apart, and a comeback measured in scripts is not the same as a comeback measured in money.
CEO Mike Doustdar marks one year in the job on 7 August. He spent that year telling a 103-year-old company to move faster, and it did. What the market is repricing is not the speed. It is the destination.
What Happened
Novo Nordisk released second-quarter results on 4 August, a day earlier than scheduled. Adjusted sales came in at DKK 78,488 million, up 7% at constant exchange rates. Adjusted operating profit was DKK 33,389 million, up 11%, roughly 16% ahead of consensus. The company raised full-year adjusted guidance for both sales and operating profit to a range of 0% to minus 6% at constant exchange rates, up from minus 4% to minus 12% set in May.
Read that guidance again. The good news is that the year is now expected to be, at worst, 6% smaller than last year.
Reported numbers tell a different story, and the gap between them is the whole point. Reported second-quarter sales grew 3% and reported operating profit fell 16%, dragged down by DKK 6.3 billion of non-cash impairments on pipeline assets, including DKK 4.0 billion on monlunabant. Across the first half, reported sales were DKK 175,311 million against adjusted sales of DKK 148,551 million. The DKK 26.8 billion difference is a first-quarter reversal of US sales rebate provisions tied to the 340B Drug Pricing Program. Novo states plainly that the reversal has no cash impact.
That single accounting entry is 15% of everything Novo Nordisk booked as revenue in the first half of 2026.
The Wegovy pill, launched in the US on 5 January, has passed 5 million prescriptions. Weekly US prescriptions exceeded 265,000 in the week ending 17 July. Management told the earnings call that the pill lifted Novo’s obesity market share from roughly 30% to roughly 45% on IQVIA sell-in data.
And the pill still missed. Second-quarter pill revenue of DKK 3.22 billion came in just under the DKK 3.27 billion analysts expected, which Novo attributed to inventory destocking. US injectable Wegovy sales also came in light. Copenhagen shares fell as much as 5% the next morning. The ADR closed 4 August down about 6% at $44.26.
The Backstory
Novo Nordisk invented this market and then lost the lead in it. Semaglutide created the modern obesity drug category; Eli Lilly’s tirzepatide out-performed it on weight loss, and Lilly took the US injectable market. Doustdar, a 33-year Novo veteran and the first non-Danish CEO in company history, was hired in August 2025 to make a consensus-driven insulin company behave like a consumer company.
The cultural changes are real and, in fairness, sensible. He works from an open floor with no office. He has pushed teams to benchmark against competitors rather than against their own history. He told the Journal that parts of the organisation had been paralysed by further analysis and by consensus decision-making, and that keeping up in a consumer-driven market requires a low ego.
But the product decision that actually moved the share needle was made before he arrived. Oral semaglutide has been in development for a decade; Rybelsus reached the market in 2019. The FDA approved the 25 mg Wegovy pill for obesity on 22 December 2025. Novo launched it in January into every channel at once: retail pharmacy, commercial insurance, telehealth, and cash-pay through GoodRx at more than 70,000 pharmacies.
The launch worked. It also arrived with the price tag attached.
The Plan
Novo’s strategy is now legible, and it is a distribution strategy rather than a science strategy.
The company is competing on friction. The pill needs no refrigeration, no needle, and no cold chain, which lets it move through channels the injection cannot reach cheaply, including telehealth and international markets with weak specialty pharmacy infrastructure. Novo launched the pill in the UAE in June and the UK in July, with more markets to come. In the UAE, where a rival oral GLP-1 had launched a month earlier, Novo says the Wegovy pill took roughly half the oral segment.
The company is also competing on price, though it does not describe it that way. Self-pay pricing for the pill runs $149 a month at 1.5 mg and 4 mg and $299 at 9 mg and 25 mg. The injection is $349 a month, and the high-dose 7.2 mg pen is $399. Commercially insured patients can pay as little as $25.
Meanwhile the rest of the portfolio is being written down. The ZEUS trial of ziltivekimab in cardiovascular disease missed its primary endpoint with a hazard ratio of 0.99. CagriSema, the intended next-generation flagship, delivered 15.2% weight loss against tirzepatide in the REIMAGINE 4 head-to-head, clearing non-inferiority on weight but not on glucose control. A US regulatory decision on CagriSema in obesity is expected around the end of 2026.
So the plan reduces to this: defend the installed base with a cheaper, more convenient version of the molecule you already own, and buy time for the pipeline.
The Business Model Angle
Here is the arithmetic that makes this a business model story rather than a quarterly earnings story.
In the first quarter, the US branded obesity market grew volume by about 85%. Novo’s US adjusted sales fell 11%. Group gross margin came in at 80.6% against 83.5% a year earlier. Units went up, dollars went down, and margin went with them. The Most Favored Nation pricing framework and the shift into cash-pay channels did the rest.
That is what happens when a company stops selling a scarce molecule and starts selling a convenience format. Scarcity supports price. Convenience does not, because convenience is copyable and the copy usually arrives cheaper.
It arrived on 1 April. The FDA approved Lilly’s orforglipron, branded Foundayo, and Lilly began shipping through LillyDirect on 6 April at $149 a month for the starting self-pay dose, $25 with commercial insurance, and $50 for eligible Medicare Part D patients from 1 July. Same price. Fewer rules: Foundayo can be taken at any time of day with food or water, while the Wegovy pill must be swallowed on an empty stomach with a small sip of water, 30 minutes before anything else.
The manufacturing difference is where this gets structural. Semaglutide is a 31-amino-acid peptide with roughly 1% oral bioavailability, versus about 89% for the subcutaneous injection. Novo compensates with dose. The injection delivers 2.4 mg per week. The pill delivers 25 mg per day, which is 175 mg per week, roughly 73 times the peptide per patient per week, each tablet also carrying 300 mg of the SNAC absorption enhancer that gets it past stomach acid.
Novo has said it can supply the launch without restrictions, and so far it has. But this is the shape of the trade: Novo is fighting a price war using a product that consumes dramatically more of the input it spent a decade building capacity for, against a competitor whose product is a small molecule made in ordinary chemical plants and which Lilly says it can scale globally without supply constraints.
One more comparison, from the same week. Lilly’s second-quarter revenue was $23.0 billion, up 48%, at an 86.3% gross margin. Mounjaro and Zepbound together did $14.9 billion. Novo’s entire adjusted quarterly sales, converted at the company’s own implied rate, were about $12.1 billion. Lilly’s two incretin brands now out-earn all of Novo Nordisk. Lilly’s stock rose 4% on its print. Novo’s fell 6%.
The Risk
The bull case is that this is a transition quarter and the volume converts to value later, once the price-cutting stops and the installed base compounds. Chronic medication is sticky, and Novo says the Wegovy franchise still leads branded obesity on new patient starts.
Four things would break that.
The second half is worse by the company’s own account. Management flagged lower realised prices, reduced obesity coverage in Medicaid, and the loss of exclusivity on semaglutide as headwinds. Guidance was raised into a still-negative range for a reason.
The 340B reversal does not repeat. DKK 26.8 billion of first-half reported revenue was an accounting true-up with no cash attached. Anyone anchoring on reported growth is anchoring on something that will not be there in 2027.
Convenience gaps close fast. Novo’s oral monopoly lasted roughly three months. Foundayo prescriptions doubled in the month before Lilly’s call, and new patient starts reached nearly one in four. The dosing restrictions on Wegovy pill are a permanent feature of the SNAC chemistry, not a launch teething problem.
The pipeline is not currently covering the gap. ZEUS failed. CagriSema cleared a lower bar than the market wanted. DKK 6.3 billion was impaired this quarter alone. The next-generation story that would justify a re-rating is not yet on the table.
Doustdar’s own framing is the tell. He told the Journal that Novo has work to do to win the market’s trust, and that he tells his team not to do anything differently, to keep performing, and that the market will follow, we just do not know when. That is a claim that the market is mispricing execution. The alternative reading is that the market has correctly priced a change in what the business is.
Quick Questions
Did Novo Nordisk actually beat expectations? Yes. Adjusted operating profit of DKK 33,389 million came in roughly 16% above consensus, and the company raised full-year guidance for the second time in 2026.
Then why did the stock fall? Raised guidance still implies a full-year decline of up to 6% on an adjusted basis. Wegovy pill revenue missed slightly, US injectable sales were light, and the profit beat leaned on rebate adjustments rather than underlying pricing.
Is the Wegovy pill cheaper than the injection? Yes, for self-pay patients. The pill runs $149 to $299 a month depending on dose. The injection is $349, and the 7.2 mg high-dose pen is $399.
What is the 340B reversal? A release of previously booked US sales rebate provisions worth DKK 26.8 billion, taken in the first quarter. It flows through reported revenue and profit but carries no cash.
Who is winning the GLP-1 market? On revenue, Lilly, by a widening margin. Novo leads on branded obesity new patient starts in the US and has taken oral share fast, but it is doing so at lower realised prices.
The Business Model Analyst Take
The most useful thing about this quarter has nothing to do with drugs.
Novo Nordisk had a business model built on a scarce, hard-to-manufacture molecule sold into reimbursed systems at high margin. It is converting into a business model built on convenience, sold partly direct to consumers at cash-pay prices, in a category where the convenience feature has already been matched by a rival with a cheaper cost structure. Both are viable businesses. They are not worth the same multiple, and the market is not confused about which one it is being asked to buy.
The trap here is the one that catches most incumbents who launch a cheaper version of their own product to defend share. The metric that improves first is the one that feels like winning: prescriptions, patients, share of new starts. The metric that deteriorates is the one that pays for everything: realised price per patient. Novo’s first quarter is the cleanest illustration you will see this year, with 85% market volume growth alongside an 11% decline in US sales.
Doustdar is right that speed and low ego matter in a consumer market. What he has not yet answered publicly is the harder question: if the pill is the future, what is the durable reason a patient chooses Novo’s pill over Lilly’s at the same price, once both are on the shelf and only one of them requires you to skip breakfast?
Until that answer exists, “keep performing and the market will follow” is a request for patience rather than a strategy. The market’s response so far has been to ask what, exactly, it is waiting for.
